Background
Idiopathic pulmonary fibrosis (IPF) is an irreversible, progressive, fibrotic lung disease, in which the lung tissue becomes thick and scarred, reducing oxygenation of the blood and resulting in end organ damage [
1,
2]. In the United States (US), IPF has an estimated annual incidence between 5.8 and 16.3 per 100,000 people per year and a prevalence of 13 to 20 cases per 100,000 [
3‐
5]. The majority of patients are male and the risk of IPF for someone age 75 years is 8 times that of someone aged 45 to 54 years [
6,
7]. Without treatment, the median survival in patients with IPF is 2–4 years after diagnosis [
7,
8].
In 2014, the US Food and Drug Administration approved the first two antifibrotic therapies for IPF pirfenidone and nintedanib [
9,
10]. In clinical trials, both antifibrotic therapies slowed disease progression as measured by a reduction in the decline in forced vital capacity compared to placebo [
11‐
13]. Although the trials were individually underpowered for assessment of overall survival, analysis suggests treatment with either drug will improve overall survival compared to best supportive care [
14‐
16].
Analyses of data on US Medicare beneficiaries have estimated that the annual cost of IPF to the US healthcare system, excluding medication costs, is $2 billion [
17]. In particular, respiratory-related hospitalizations are associated with an elevated risk of mortality and a significant cost burden [
18‐
21] There is limited real-world data on the impact of pirfenidone and nintedanib on healthcare resource utilization (HRU) and costs among patients with IPF. This retrospective cohort study compared treatment patterns, HRU, and direct healthcare costs between patients with IPF insured through commercial or Medicare Supplemental plans who were treated with pirfenidone or nintedanib.
Methods
Study design and data source
This observational retrospective cohort analysis utilized de-identified US administrative claims data covering October 1, 2014, to June 30, 2018, from three IBM MarketScan Databases: the Commercial Claims and Encounters (Commercial), the Medicare Supplemental and Coordination of Benefits (Medicare), and the Early View Databases [
22]. The commercial database includes healthcare data of employees and their dependents covered under a variety of fee-for-service and managed care health plans. The Medicare database contains the healthcare experience of retirees with Medicare supplemental insurance paid for by employers. The Commercial and Medicare databases provided data access for the period of October 1, 2014, through September 30, 2017. Each database captures the inpatient medical, outpatient medical, and outpatient prescription drug data for its respective covered population, and together form a nationally representative sample of insured individuals living in the US.
The Early View database includes the same components as the Commercial and Medicare databases for the period of October 1, 2017, through June 30, 2018. Claims are available in the Early View database within 45 days of the end of the service month, and previous analysis has shown that over 97% of drug claims are fully adjudicated within the 30 days of the service date making it appropriate to use for treatment pattern analysis but not for HRU and cost analyses.
Study variables were based on enrollment information, International Classification of Diseases, 9th and 10th Revision, Clinical Modification (ICD-9-CM and ICD-10-CM) codes, Current Procedural Terminology 4th edition codes, Healthcare Common Procedure Coding System codes, and National Drug Codes. All study data were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). The databases used in the study are fully de-identified and compliant with the HIPAA. Research using the MarketScan Research Databases falls under Title 45 of the Code of Federal Regulations Part 46.101(b)(4) exemption from Institutional Review Board review because the databases contain only information that cannot be used to identify study subjects. As the data were de-identified, consent from patients was not sought.
Patient selection and cohort assignment
The study population consisted of patients with at least one outpatient pharmacy claim for pirfenidone or nintedanib from October 1, 2014, to June 30, 2018. The first such claim during the study period was set as the index date. Patients were required to be at least 40 years old on the index date, have continuous enrollment with medical and prescription coverage for at least 12 months before the index date (baseline period), and have at least one non-diagnostic inpatient or outpatient claim with an diagnosis code for IPF (ICD-9-CM: 516.3 and 516.31; ICD-10-CM: J84.112) between the baseline period and June 30, 2018. Patients were excluded if they had evidence of other interstitial lung diseases (hypersensitivity pneumonitis, diffuse connective tissue disease, rheumatoid arthritis and other inflammatory polyarthropathies, radiation fibrosis, pneumoconiosis, asbestosis, silicosis or talcosis, berylliosis and other inorganic dusts, unspecified pneumoconiosis, sarcoidosis) between the index date and June 30, 2018.
Dataset development
Three datasets were constructed from the set of patients who met the above criteria: the treatment patterns dataset, the variable-length HRU and cost while persistent dataset, and the 12-month fixed-length HRU and cost dataset. Patients in each dataset were stratified into two cohorts based on the antifibrotic received on the index date: pirfenidone or nintedanib.
The treatment patterns dataset contained all eligible patients and followed them from 12 months before their index date until the earliest of the following: inpatient death, end of continuous enrollment, or June 30, 2018 (end of the Early View data). The variable-length HRU and cost while persistent dataset comprised patients who had an index date on or before September 30, 2017 (end of non-Early View data). Patients were followed from 12 months before their index date until the earliest of the following: inpatient death, end of continuous enrollment, treatment discontinuation (defined below), or September 30, 2017. The 12-month fixed-length HRU and cost dataset comprised patients who had an index date on or before September 30, 2016 and at least 12 months of continuous enrollment in non-Early View data. Patients were followed from 12 months before their index date through 12 months after their index date, regardless of the length of time they persisted on their index medication.
Baseline characteristics
Demographic characteristics, including age, sex, and geographic region, were measured on the index date. Baseline clinical characteristics were measured during the baseline period and included: the Deyo-Charlson Comorbidity Index (CCI) [
23], the CCI excluding codes related to chronic obstructive pulmonary disease (COPD), supplemental oxygen use, opioid prescriptions, and claims with diagnosis codes for cardiovascular disease (including stroke specifically), COPD, cancer (including lung cancer specifically), dyspnea, and recent pneumonia (3 months preceding the index date). Patients who were treated at an Interstitial Lung Disease (ILD) Center of Excellence as identified by the zip code of the facility were also flagged. Centers of Excellence were defined as medical centers with specific expertise in the treatment of pulmonary fibrosis, as recognized by the Pulmonary Fibrosis Foundation.
Discussion
In a real-world setting, patients with IPF who were treated with pirfenidone had a longer time to discontinuation or switching and similar odds of adherence compared to patients treated with nintedanib. While persistent on index medication, patients treated with pirfenidone had 15% lower index drug costs, 11% lower respiratory-related costs, and similar all-cause costs than patients treated with nintedanib. This was in spite of higher utilization of all-cause and respiratory-related inpatient services while they were persistent on their index medication. Among the subset of patients with 12 months of follow-up data, all-cause and respiratory-related adjusted annual costs were similar regardless of index medication; however, index drug-related costs were lower for patients who indexed on pirfenidone.
Adherence to and persistence with antifibrotic therapies in IPF are important for maintaining treatment benefits and slowing lung function decline; however, there is limited existing data on treatment patterns as pirfenidone and nintedanib have only been recently approved to treat IPF in the US [
25‐
27]. Two recent studies of US Medicare and commercially-insured patients found that those who indexed on pirfenidone had higher adherence and longer persistence than patients who indexed on nintedanib; however, the mean follow-up time was less than half of that reported in this study and there are difference in the patient populations and patient selection criteria [
25,
26]. In an analysis of Swedish patients with IPF treated with pirfenidone, 24.7–41.8% (depending on data source) were persistent at 1 year compared with over 50% in our study; however, they used a 30-day gap to define discontinuation compared to the 60-day gap used in this study [
27]. Treatment pattern analysis was not available on patients who indexed on nintedanib in the Swedish analysis due to low utilization during the study time frame.
To our knowledge, no analyses comparing healthcare costs between IPF patients treated with pirfenidone and IPF patients treated with nintedanib have been published. Prior to the approval of pirfenidone and nintedanib, analyses of Medicare and commercially insured patients with IPF have estimated mean annual healthcare costs ranging from $26,000 to $ 59,000 and mean annual medical costs (total costs minus pharmacy costs) ranging from $20,000 to $52,000 [
17,
20,
28]. In our analysis, index medication costs comprised a large proportion of total costs. When index medication costs were excluded, mean adjusted annual costs for patients treated with pirfenidone and nintedanib were $40,756 and $29,809 respectively, which are within the ranges of the previous estimates of mean healthcare costs of IPF prior to the introduction of antifibrotic therapies.
A previous analysis has shown that acute exacerbations in the first 6 months after diagnosis of IPF and a greater decline in forced vital capacity are associated with increased healthcare utilization and shorter overall survival [
21]. In studies of commercially insured patients with IPF prior to the approval of pirfenidone and nintedanib, over 37% of patients had at least one all-cause inpatient admission during a 1-year follow-up period [
20,
29]. Treatment with antifibrotics has been demonstrated to reduce the decline in lung function with the assumption that this will reduce healthcare utilization and improve overall survival, but effective treatment requires that patients are adherent to and persistent on medication. Future real-world studies can examine whether the differences in medication persistence observed in this analysis persist as more data become available and translate to improved clinical and economic outcomes.
Limitations
There are several limitations that should be considered when interpreting the findings of this study. First, as with any analysis of healthcare claims data, the adherence and persistence results reflect patterns in prescription fills (and not necessarily use) of the index medications; therefore, they may not fully capture usage patterns of antifibrotic therapy among patients with IPF. Second, unadjusted results for healthcare utilization did not account for potential differences in patient characteristics between treatment groups. Third, cost comparisons were adjusted for some potential confounders; however, residual confounding may exist due to the lack of clinical data included in administrative claims data or other unobserved differences between cohorts. Because patients were selected based on initiation of pirfenidone vs. nintedanib and clinical notes are not available, we were not able to control for years since initial diagnosis. Measures of disease severity, such as results of pulmonary function tests and GAP stage, were also not available. Fourth, only a small number of patients had 12 months of non-Early View follow-up data, so the analysis may be underpowered to detect differences in HRU and costs. Fifth, the proportions of patients with specific utilization types measured during the persistent period did not account for variable follow-up time. Sixth, prior to the approval of these medications there was no effective treatment for IPF; therefore, patients in this analysis may be sicker on average than future patients who have access to these medications upon initial diagnosis. Patients who did not survive 12 months after index medication initiation did not meet the continuous enrollment criteria for the fixed 12-month follow-up outcomes. Finally, analysis was restricted to patients with commercial or Medicare Supplemental insurance and findings may not extend to patients with other types of insurance or no insurance.
Conclusions
After controlling for patient differences, IPF patients on pirfenidone remained on index therapy significantly longer than nintedanib patients. While patients were persistent on their index medication, weighted index drug costs and respiratory-related total costs were significantly lower among patients treated with pirfenidone compared to nintedanib patients.
Acknowledgments
Medical writing services were provided by Jessamine P. Winer-Jones, Ph.D. of IBM Watson Health. These services were paid for by Genentech, Inc. This research was presented in part at the American College of Chest Physicians (CHEST) Annual Meeting 2019, October 19–23, 2019, New Orleans, LA.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.